NCT02411656: MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: TNBC patients are not required to have IBC to be eligible
Exclusions: Patients with known, active, unstable central nervous system (CNS) metastases and/or carcinomatous meningitis that require treatment- see trial for details

Comments are closed.

Up ↑